Navigation Links
ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
Date:8/30/2007

Dr. Peter Farrell to remain Chairman of the Board

SAN DIEGO, Aug. 30 /PRNewswire-FirstCall/ -- ResMed Inc. (NYSE: RMD) announced today that its board of directors has unanimously approved a succession plan for executive management of the company. Effective January 1, 2008, Kieran T. Gallahue will be promoted to Chief Executive Officer and will join the board of directors. Mr. Gallahue, 44, will succeed Dr. Peter C. Farrell, 65. As of January 1, 2008, Dr. Farrell will relinquish his position as CEO, but will continue serving as Executive Chairman of the Board until June 30, 2008, when he will become non-executive Chairman.

(Photo: http://www.newscom.com/cgi-bin/prnh/20070830/LATH125-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20070830/LATH125-b)

"Since joining ResMed in 2003, Kieran has demonstrated strong leadership qualities," said Dr. Farrell. "He has been instrumental in improving our operational execution, targeting our research and development efforts, focusing our commercial teams to better serve patients and customers, while strengthening the depth of our management. He has earned the respect of our employees and customers. He has the full support of myself and the Board, and is the right person to succeed me as ResMed's Chief Executive Officer."

"Since founding the company in 1989, I have been passionate about the need to increase awareness of sleep-disordered breathing among both the public and the medical community, as well as the need to increase understanding of the deleterious consequences of the dise
'/>"/>

SOURCE ResMed Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Vietnamese Scientists Unravel Genetic Code Of Bird Flu Virus
2. Financial Allowances Being Offered To Poor Vietnamese HIV Carriers
3. Gene Bias: Onomastics of Shared Surnames among Men Reveals Genetic links
4. AIDS Funding Grants Dependant on Tracking Patients Names Efficiently
5. Health Minister Wants Names of Uncooperative Hospital Consultants
6. Chinese PLA Names Bogus Army Medical Bodies Selling Fake Drugs
7. Over 50 Vietnamese Girls Faint Due to Mass Hysteria
8. All U.S. States To Begin Names-Based Reporting of HIV Cases by End of 2007
9. Rajasthan Directs Doctors to Prescribe Medicines by Generic Names
10. UNAIDS Chief Appeals for Projects to Battle AIDS/HIV
11. EU medical chief says Europe ready for bird flu

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...Researchers at Ben-Gurion University of the Negev ... skin tumors, including melanomas that aren,t visi...the OSPI instrument (Optical Spectro-Polarimetric ...e never been seen before - including melanoma in p...ns and were awaiting surgery for their removal. Th...
(Date:11/24/2009)...Mid-Winter Meetings Jan. 27Feb. 2, 2010, at the Al...his year, SNM joins its annual Mid-Winter Educatio...cational Symposium of the American College of Nucl...r Imaging Summit and the Clinical Trials Network C...icipants an outstanding range of scientific conten...
(Date:11/24/2009)...sed sevenfold, study finds, , , TUESDAY...c-resistant infections normally found in the commu...tpatients, raising the risk that inpatients could ... to 2006, researchers found a sevenfold increase i...sistant Staphylococcus aureus (MRSA) infections....
(Date:11/24/2009)...ice to be coupled with Stem Cell Therapy. , ...24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB... a manufacturer of lasers regarding the developmen...ed by Entest and used in conjunction with several ...ntest. These therapies are aimed at increasing eff...
(Date:11/24/2009)...o Get a Leg Up From the American Podiatric Medical...Md. (Vocus) November 24, 2009 -- The average perso... that number dramatically increases during the hol...continue making their holiday travel plans, it&rsq...runt of aches and pains while on the road. , , , ...
Breaking Medicine News(10 mins):Health News:New device enables early detection of cancerous skin tumors -- Ben Gurion U. 2Health News:SNM's Conjoint Mid-Winter Meetings offer 4 scientific meetings in 1 location 2Health News:MRSA Creeping Into Hospitals From the Outside 2Health News:MRSA Creeping Into Hospitals From the Outside 3Health News:Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment 2Health News:Keep Holiday Travel Foot-Friendly 2Health News:Keep Holiday Travel Foot-Friendly 3
...egarding the outbreak of the deadly Rift valley Fe...warned against consumption of raw milk. // ...en borderline areas, is safe from the viral livest...due to hygienic concerns but also due to the fact ...
...linois at Chicago study published in the January i...ority of fertility clinic Web sites does not adher...nes. The study also found that services offer... offer financial incentives. Many consumers re...
...ts that doctors should advise and persuade patient...heir partners and bring// them for check up and tr...g kits or drugs in order to help reduce infection ...ransmitted infections often makes this difficult. ...
...ency, Pharmac, is in the process of doing away wit... Pharmac intends to phase out the ‘Aropax’ brand ... ‘Loxamine’. It is estimated that Aropax is used b...e, except for the appearance and the packaging. Fu...
...ake Forest University Baptist Medical Center are h...lving 83 other sites that will test 3,000 patients... is good for heart failure patients. Though d...he group of patients who primarily have heart fail...
... we shed tears. But exactly what our tears are mad... A new study sheds some light on the complex desig...call tear film, which is made up of three distinct...layer of fatty, oily substances collectively calle...
Other Medicine News:Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 2Health News:Experts Warn Against Raw Milk Following Rift Valley Fever Outbreak in Kenya 3Health News:Fertility Clinic Web Sites Doesn’t Adhere to Ad-Guideline 2Health News:New International Study to Test Exercise in Heart Failure Patients 2Health News:New International Study to Test Exercise in Heart Failure Patients 3Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 2Health News:Tears Reveal Some of Their Deepest Secrets to Researchers 3
(Date:11/24/2009)...,Nov.24/PRNewswire-Asia/--HuifengBio-Pharmaceutica...eveloperandproducer,ofplantextractsandpharmaceutic...landfoodproductioninXi,an,China,todayreportedthati...revenues. , RevenuesforthequarterendedSept.30...om$3,534,623forthesamequarterin2008.Netincome,amou...
(Date:11/24/2009)...OOD,Calif.,Nov.24/PRNewswire-FirstCall/--IPCTheHos...alhospitalistphysiciangrouppracticecompany,announc...t,wasnamedby ACPHospitalist asoneofthe2009TopTenHo...2009issueofthemagazine. ,, Dr.Vaidyanhasbeenapr...vesasdirectorofhospitalmedicineatSt.Mary,sHealthCe...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--ZimmerHoldings,Inc....atinginthe21stAnnualPiperJaffrayHealthCareConferen...ternTime. ,, Alivewebcastofthepresentationcanbe...://investor.zimmer.com .Thewebcastwillbearchivedfo...any ,, Foundedin1927andheadquarteredinWarsaw,I...
Breaking Medicine Technology:Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 2Huifeng Bio-Pharmaceutical Technology Reports 26% Quarterly Revenue Increase 3IPC The Hospitalist Company's Philip Vaidyan, M.D. Named a Top Hospitalist of 2009 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 1Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 2Watson Pharmaceuticals Resumes Shipment of INFeD 28R 29 28Iron Dextran Injection USP 29 51309 3Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 1Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 2Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 51307 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 1Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 2Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 3Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 4Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 5Bioniche Life Sciences Inc and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin 28TM 29 4712 6
...lood pressure reductions of 30.8 mm Hg,systolic bl...pressure (DBP),at five weeks and 21.1/19.3 mm Hg (... of patients with severe hypertension, AVAL...4.6 mm Hg (SBP/DBP), at 8 weeks, and 22.1/11.6 mm...ectively for irbesartan and HCTZ alone, in a study...
...Proprietary siRNA Molecule in Acute .... 19 Quark Pharmaceuticals, Inc., a,development-s... and,developing novel RNA interference-based thera...temic dosing in humans of its proprietary product,... developed by Quark for,the treatment of Acute Ren...
Other Medicine Technology:Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 2Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 3Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 4Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 5Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 6Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood 7Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 2Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 3Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans 4
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: